7th Cancer Scientific Forum of the Cancéropôle Lyon Auvergne Rhône-Alpes
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
7th Cancer Scientific Forum of the Cancéropôle Lyon Auvergne Rhône-Alpes
Authors
Keywords
-
Journal
mAbs
Volume 4, Issue 4, Pages 434-444
Publisher
Informa UK Limited
Online
2012-06-29
DOI
10.4161/mabs.20869
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biosimilar, Biobetter, and Next Generation Antibody Characterization by Mass Spectrometry
- (2012) Alain Beck et al. ANALYTICAL CHEMISTRY
- Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway
- (2012) J. Honeychurch et al. BLOOD
- Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
- (2012) G. Salles et al. BLOOD
- A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
- (2012) L. H. Sehn et al. BLOOD
- Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study
- (2012) Takashi Ishida et al. JOURNAL OF CLINICAL ONCOLOGY
- Which are the antibodies to watch in 2012?
- (2012) Janice M. Reichert mAbs
- Marketed therapeutic antibodies compendium
- (2012) Janice M. Reichert mAbs
- Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma
- (2011) H. C. Kluin-Nelemans et al. ANNALS OF ONCOLOGY
- Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for Treatment of Refractory Chronic Lymphocytic Leukemia
- (2011) Ginah Nightingale ANNALS OF PHARMACOTHERAPY
- CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101
- (2011) M. Jak et al. BLOOD
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
- (2011) W. Alduaij et al. BLOOD
- Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
- (2011) G. Niederfellner et al. BLOOD
- A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo
- (2011) Elizabeth Ward et al. BRITISH JOURNAL OF HAEMATOLOGY
- SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
- (2011) V. Blanc et al. CLINICAL CANCER RESEARCH
- Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
- (2011) A. D. Ricart CLINICAL CANCER RESEARCH
- Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies
- (2011) G. Cartron et al. CLINICAL CANCER RESEARCH
- Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
- (2011) R. J. Kreitman et al. CLINICAL CANCER RESEARCH
- Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
- (2011) M. Steiner et al. CLINICAL CANCER RESEARCH
- Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Antibody Conjugate Therapeutics: Challenges and Potential
- (2011) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- Brentuximab Vedotin (SGN-35)
- (2011) J. Katz et al. CLINICAL CANCER RESEARCH
- Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders
- (2011) Lyudmyla Derby et al. Future Oncology
- World Antibody Drug Conjugate Summit Europe
- (2011) Alain Beck et al. mAbs
- Biosimilar, biobetter and next generation therapeutic antibodies
- (2011) Alain Beck mAbs
- Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies
- (2011) Alain Beck et al. mAbs
- Antibody-based therapeutics to watch in 2011
- (2011) Janice M. Reichert mAbs
- Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101
- (2011) S. Dalle et al. MOLECULAR CANCER THERAPEUTICS
- Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
- (2011) W. Schaefer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose
- (2011) C. Ferrara et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma
- (2010) Francesco D’Amore et al. BRITISH JOURNAL OF HAEMATOLOGY
- Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells
- (2010) Michaela Patz et al. BRITISH JOURNAL OF HAEMATOLOGY
- Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma
- (2010) G. O. Negrea et al. HAEMATOLOGICA
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
- (2010) Gilles Salles et al. LANCET
- European Medicines Agency workshop on biosimilar monoclonal antibodies
- (2010) Janice M. Reichert et al. mAbs
- Metrics for antibody therapeutics development
- (2010) Janice M. Reichert mAbs
- Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis
- (2009) R M Thurlings et al. ANNALS OF THE RHEUMATIC DISEASES
- A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
- (2009) Andres Forero-Torres et al. BRITISH JOURNAL OF HAEMATOLOGY
- EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
- (2009) D. O'Mahony et al. CLINICAL CANCER RESEARCH
- Antibody-Drug Conjugate Targets
- (2009) B. Teicher CURRENT CANCER DRUG TARGETS
- Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
- (2009) Ranjana Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- B-cell-directed therapies for autoimmune disease
- (2009) Thomas Dörner et al. Nature Reviews Rheumatology
- Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
- (2008) G. Salles et al. BLOOD
- Endosialin Protein Expression and Therapeutic Target Potential in Human Solid Tumors: Sarcoma versus Carcinoma
- (2008) C. Rouleau et al. CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now